Clinical Trial Update: Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for flotetuzumab in primary induction failure or early relapse acute myeloid leukemia; the study is terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Flotetuzumab (flotetuzumab)

Snippet

Sponsor: MacroGenics | Conditions: AML | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-01-30